Medicines shortages attract attention because they are visible. Patients are affected. Pharmacists spend time sourcing alternatives. Procurement teams look for stock. Healthcare organisations implement contingency plans.
The shortage becomes the focus.
But what if shortages are not the problem?
What if they are simply the most visible symptom of changes that have been developing for months, or even years?
One of the first lessons learned in drug discovery and development is that success rarely comes from maximising a single parameter.
A molecule may demonstrate exceptional activity in the laboratory, but that alone is not enough. If it cannot be manufactured reliably, lacks suitable pharmacokinetic properties, presents safety concerns, or proves difficult to develop, it is unlikely to become a successful medicine.
The reality is that drug development is an exercise in balance. Scientists spend years optimising multiple variables simultaneously, recognising that focusing too heavily on one characteristic often comes at the expense of another.
The same principle applies to complex systems more broadly.
The Challenge of Optimisation
In healthcare, affordability is an important objective. The contribution of generic medicines to improving access and reducing costs is undeniable.
However, cost is only one dimension of performance.
Availability matters.
Patient access matters.
Continuity matters.
Resilience matters.
Long-term sustainability matters.
The challenge is that some of these factors are easier to measure than others.
Procurement savings can be quantified and reported. The value of resilience is far more difficult to capture. It is rarely visible until it is tested.
As a result, there is a natural tendency to focus on the metrics that are most visible and most easily measured.
The Difference Between Causes and Outcomes
One of the fundamental principles in science is that observable events are often lagging indicators.
By the time a measurable effect appears, the underlying conditions responsible for that outcome may have been developing for a considerable period of time.
This distinction between leading and lagging indicators is important.
Lagging indicators tell us what has happened.
Leading indicators provide insight into what may happen next.
Shortages, supply disruptions and price concessions are all examples of outcomes that become visible once underlying pressures have reached a certain point.
The more interesting question is what happened beforehand.
Changes in supplier participation.
Manufacturing constraints.
Shifts in demand.
Commercial pressures.
Increasing market concentration.
These developments rarely emerge overnight. They evolve gradually, often remaining largely invisible until their effects become apparent elsewhere in the system.
Looking Beyond the Outcome
In scientific research, understanding the factors that drive an outcome is often more valuable than measuring the outcome itself.
The same principle applies to medicines supply.
Responding to shortages will always be important. However, understanding the conditions that precede them may be even more valuable.
The earlier emerging risks can be identified, the greater the opportunity to understand, anticipate and potentially mitigate their impact.
Are We Measuring the Right Things?
The objective is not to maximise a single variable.
It is to understand the relationship between multiple variables and optimise the system as a whole.
Drug discovery and development has always operated on this principle.
Perhaps there is a lesson in that for healthcare more broadly.
The most effective systems are rarely those that excel at one thing. They are the systems that achieve the right balance across many competing priorities.
Which raises a final question.
If shortages are the outcome, are we paying enough attention to the indicators that appear before them?